A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens

Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of stage IIIB/IV NSCLC; * Must have received 1 or 2 prior chemotherapy regimens for advanced NSCLC and now have progressive disease; * Must have recovered from any treatment-related toxicities prior to registration, except for alopecia, grade 1 fatigue, or grade 1 neurotoxicity; * A current cigarette smoker (minimum of 10 cigarettes per day for \>= 1 year and have a positive test for cotinine) despite advice and support to quit; * Age \>= 18 years; * ECOG PS 0-1 and predicted life expectancy \>= 12 weeks; * Previous surgery is permitted provided that wound healing has occurred prior to registration; * Adequate hematopoietic, hepatic and renal function defined as follows: ANC \>= 1.5 x 10\^9/L, platelets \>= 100 x 10\^9/L, bilirubin \<= 1.5 x ULN, ALT \<= 2.5 x ULN (or 5 x ULN in case of liver metastases), creatinine \<= 1.5 x ULN; * No prior treatment with Tarceva or gefitinib (or other drug with significant activity against EGFR (eg, cetuximab and/or ZD6474)); * Patients with reproductive potential must practice effective contraceptive measures throughout the study. Women of child-bearing potential must provide a negative pregnancy test within 14 days prior to registration; * Accessible for repeat dosing and follow-up. Exclusion Criteria: * Any concurrent anticancer cytostatic or cytotoxic chemotherapy; * Concomitant CYP3A4 or CYP1A2 inducers/inhibitors (or during 14 days prior to study) with the exception of tobacco; * Other active malignancies, unless disease-free and without cancer-specific therapy for at least the last 5 years. Basal or squamous cell skin cancers are not excluded; * Significant history of cardiac disease unless the disease is well-controlled; * Active or uncontrolled infections or serious illnesses or medical conditions that could interfere with the patient's ongoing participation in the study; * History of any psychiatric condition that might impair the patient's ability to understand or comply with the requirements; of the study or to provide informed consent. * Gastrointestinal abnormalities, including inability to take oral medication, requirement for IV alimentation, active peptic ulcer or prior surgical procedures affecting absorption; * Clinically significant ophthalmologic abnormalities; * Pregnant or breast-feeding females. Males or females not practicing effective birth control; * Symptomatic brain metastases which are not stable, require steroids, or that have required radiation within the last 28 days; * History of allergic reactions attributed to compounds of similar chemical or biologic composition to the study drug;